CellRapeutics™ In Vivo Peripheral Blood Mononuclear Cell (PBMC) Engineering Service

The advancement of cell-based immunotherapies into clinical practice frequently encounters major obstacles, including resource-intensive ex vivo production processes, limited in vivo longevity of therapeutic cells, and the challenge of tumor antigen diversity. Creative Biolabs' CellRapeutics™ in vivo PBMC engineering platform overcomes these fundamental limitations by facilitating the direct in vivo genetic modification of a patient's own circulating immune cells. Utilizing proprietary, cell-targeted delivery vectors, we achieve efficient and specific gene transfer without the need for external cell manipulation. Our strategy eliminates the lengthy and costly ex vivo manufacturing step, significantly accelerating development timelines and reducing production expenses.

Introduction

Peripheral blood mononuclear cells (PBMCs) represent a heterogeneous population comprising critical immune cells such as lymphocytes and monocytes. Beyond serving as an accessible peripheral blood sample, PBMCs can reflect the systemic immune status of the body. They are widely utilized to assess disease-associated immune response features, screen for predictive biomarkers, and develop personalized immunotherapy strategies. Currently, the isolation of PBMCs predominantly relies on density gradient centrifugation methods, which effectively separate whole blood into layers and enrich mononuclear cells. Further purification steps, including red blood cell lysis, enhance cellular purity, thereby providing a reliable cell source for subsequent functional, molecular, and genomic analyses.

Fig.1 PBMC isolation workflow.¹

CellRapeutics™ In Vivo Peripheral Blood Mononuclear Cell (PBMC) Engineering Service at Creative Biolabs

Creative Biolabs' CellRapeutics™ In Vivo Peripheral Blood Mononuclear Cell (PBMC) Engineering Service transitions CAR T-cell therapy from a complex, costly manufacturing burden to a precise, streamlined biological process occurring within the native environment. We solve the core logistical and biological challenges of ex vivo therapy by delivering the therapeutic payload directly to the patient's PBMCs in vivo, which ensures maximum cell integrity, superior T cell fitness, and a predictable path to clinical translation.

What We Can Offer

Our platform offers an integrated, end-to-end solution for in vivo PBMC development, encompassing high precision cell isolation technologies, targeted in vivo gene delivery systems, and intelligent CAR designs with built-in polarization signals to generate potent and durable cell therapies directly within the patient.

Our Service Process

Required starting materials:

• Target Antigen/Epitope Sequence: The specific CAR or T-Cell Receptor (TCR) sequence you wish to express.
• Vector Backbone Preference: Information on desired delivery vehicle characteristics (e.g., LNP composition, non-integrative viral vector type, promoter systems).
• Target Indication and Tumor Model: The specific cancer type and relevant cell lines or xenograft models for in vivo validation.

Key Steps:

Final Deliverables:

• Vector Design & Manufacturing Report: Including the final sequence, vector quality control data, and suggested scaling parameters. Comprehensive Efficacy & Persistence
• Data Package: Detailed survival curves, tumor volume measurements, and flow cytometry data tracking engineered PBMC populations over time.

Key Advantages

• Proprietary mTCM Enrichment Protocols: Optimized, patented in vivo priming and conditioning regimens designed to selectively generate and expand Modified T Central Memory cells, the gold standard for long-term immune surveillance and durability.
• Custom Multi-Targeting Vector Design: Advanced capabilities in designing and synthesizing complex genetic constructs (CARs, TCRs, or proprietary payloads) that recognize multiple tumor antigens simultaneously, offering robust defense against antigen escape.
• Biomarker-Driven Therapeutic Optimization: Specialized diagnostic services for profiling the intrinsic immune status of the PBMC population, including analysis of pathways like cGAS-STING, allowing for customized therapeutic refinement and maximizing the potential for patient response.
• Non-Integrative Safety Platform: Guaranteed use of non-replicative, non-integrative vector systems to significantly reduce regulatory concerns related to insertional mutagenesis, ensuring a safety-first approach compatible with rapid clinical translation.

FAQ

Why Choose Us?

We provide an integrated platform that transforms peripheral blood mononuclear cells into potent in vivo CAR therapies. Our approach combines computational CAR design, targeted LNP or viral delivery, rigorous humanized model validation, mandatory genome safety profiling, and scalable manufacturing protocols to deliver a safe, effective, and clinically translatable therapeutic strategy.

Customer Reviews

"Using Creative Biolabs' In vivo PBMC Development in our research has significantly improved the long-term persistence and T central memory profile of our engineered cells compared to our own ex vivo products."— D. T****n, Research Director.

"The multi-targeting delivery mechanism was essential for validating our strategy against highly heterogeneous solid tumor models, an area where single-antigen ex vivo products consistently failed."— Dr. A. P***k, Immuno-Oncology Lead.

"Creative Biolabs' commitment to understanding the intrinsic immune status, like the cGAS-STING activation pathway, allowed us to refine our therapeutic construct for maximized patient response, greatly informing our selection criteria."— S. M***r, Translational Scientist.

How to contact us?

To explore a tailored in vivo PBMC development strategy, receive project-specific technical details, or schedule a comprehensive consultation for your immunotherapy program, please contact our scientific team to initiate a collaborative discussion.

Reference

1. De Rosa, Caterina et al. "PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer." Biomedicines vol. 12,4 809. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/biomedicines12040809.